EGFR and non-small cell lung carcinoma: When used in patients with NSCLC, the combination of bevacizumab with ICIs and chemotherapy significantly prolonged patient survival compared with I + C or B + C in EGFR‐mutant but TKI‐resistant NSCLC.32